Literature DB >> 4809310

Polynucleotide immune complexes in serum and glomeruli of patients with systemic lupus erythematosus.

D Koffler, V Agnello, H G Kimkel.   

Abstract

Several types of antipolynucleotide antibodies were eluted by acid buffer or deoxyribonuclease treatment of glomeruli obtained from nine kidneys from patients with systemic lupus erythematosus (SLE). Anti-SDNA antibodies were found concentrated over serum levels in eight eluates, anti-NDNA in six eluates and anti-RNA Pr in four eluates; anti-DSRNA antibodies were not demonstrable in any eluate tested. Deoxyribonuclease treatment eluted a high incidence and greater quantity of anti-NDNA and anti-SDNA antibody, whereas anti-RNA Pr antibody was mainly eluted by acid buffer. Simultaneous studies of antibody and antigen in serial serum specimens and in glomeruli suggested that complexes of SDNA antibody or antigen excess were frequently deposited in SLE kidneys, in addition to complexes containing anti-NDNA and anti-RNA Pr. It was observed that studies of antibody titers alone were inadequate for predicting the types of complexes deposited in the kidney. Either antigen excess could obscure detection of humoral antibody or extremely high titers of antibody as observed for RNA Pr are not conducive to the formation of kidney localizing immune complexes in the absence of antigen. Immunofluorescence studies demonstrated the presence of SDNA antigen in most cases from which anti-SDNA antibody was eluted providing direct evidence for the presence of SDNA-anti-SDNA complexes in renal glomeruli. A study of complement components indicated that Clq was absent from cases in which little or no SDNA was deposited in renal glomeruli; although all nephritic kidneys demonstrated C3 deposits. Several hypotheses accounting for this observation are discussed, including the probable utilization of the alternate pathway by certain types of complexes and a direct reaction between C1q and circulating or tissue-bound NDNA or SDNA.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4809310      PMCID: PMC1910734     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  Systemic lupus erythematosus: prototype of immune complex nephritis in man.

Authors:  D Koffler; V Agnello; R Thoburn; H G Kunkel
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

2.  Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors:  P H Schur; J Sandson
Journal:  N Engl J Med       Date:  1968-03-07       Impact factor: 91.245

3.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.

Authors:  E M Tan; P H Schur; R I Carr; H G Kunkel
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

4.  Studies on chronic membranoproliferative glomerulonephritis with hypocomplementemia.

Authors:  A F Michael; N G Westberg; A J Fish; R L Vernier
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

5.  Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis.

Authors:  C Krishnan; M H Kaplan
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

6.  Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.

Authors:  R H McLean; A F Michael
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

7.  Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis.

Authors:  G A Andres; L Accinni; S M Beiser; C L Christian; G A Cinotti; B F Erlanger; K C Hsu; B C Seegal
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

8.  Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis.

Authors:  F J DIXON; J D FELDMAN; J J VAZQUEZ
Journal:  J Exp Med       Date:  1961-05-01       Impact factor: 14.307

9.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

10.  Antibodies to polynucleotides in human sera: antigenic specificity and relation to disease.

Authors:  D Koffler; R Carr; V Agnello; R Thoburn; H G Kunkel
Journal:  J Exp Med       Date:  1971-07-01       Impact factor: 14.307

View more
  47 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  Relation between serological data at the time of biopsy and renal histology in lupus nephritis.

Authors:  J C Nossent; S C Henzen-Logmans; T M Vroom; V Huysen; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  Type C RNA virus-specific antibody in human systemic lupus erythematosus demonstrated by enzymoimmunoassay.

Authors:  R C Mellors; J W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

4.  Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.

Authors:  C Liu; Y Kanamaru; T Watanabe; N Tada; S Horikoshi; Y Suzuki; Z Liu; Y Tomino
Journal:  Clin Exp Immunol       Date:  2015-07-02       Impact factor: 4.330

5.  Pharmacodynamics of recombinant human DNase I in serum.

Authors:  W S Prince; D L Baker; A H Dodge; A E Ahmed; R W Chestnut; D V Sinicropi
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

6.  Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.

Authors:  M Satoh; A Kumar; Y S Kanwar; W H Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  The significance of antibodies to poly(adenosine diphosphate-ribose) in systemic lupus erythematosus.

Authors:  E E Okolie; S Shall
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

8.  Detection of immune complexes. The use of radioimmunoassays with Clq and monoclonal rheumatoid factor.

Authors:  A Gabriel; V Agnello
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

9.  Antibodies to polyadenylic acid in patients with myasthenia gravis.

Authors:  M Fischbach; J Lindstrom; N Talal
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

10.  Enzyme-linked immunosorbent assays for antibodies to poly(A), poly dAT and histones: possibly useful tools for the evaluation of prognosis and disease activity in systemic lupus erythematosus.

Authors:  T Helve; M Gripenberg; P Kurki; A M Teppo; O Wegelius
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.